AXS-12 (reboxetine) PDUFA date

The PDUFA goal date for AXS-12 (reboxetine) in cataplexy in narcolepsy is 1 May 2027, as disclosed by Axsome Therapeutics, Inc. (AXSM).

PDUFA date
1 May 2027
Condition
cataplexy in narcolepsy

Drug identity checked against registry records

Also recorded as AXS-12; reboxetine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-05-01DayAXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSMCompany-disclosed PDUFA goal dateAnnounced review targetcataplexy in narcolepsyOpen original source
Read source excerpt

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy FDA sets PDUFA target action date of May 1, 2027

First seen: 25 Sep 2026 · Evidence last checked: 25 Sep 2026

2027-05-01DayAXS-12 (reboxetine)Axsome Therapeutics, Inc. · AXSMCompany-disclosed PDUFA goal dateAnnounced review targetcataplexy in narcolepsyOpen original source
Read source excerpt

Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027.

First seen: 02 Nov 2026 · Evidence last checked: 02 Nov 2026